HighTower Advisors
DGX icon

HighTower Advisors’s Quest Diagnostics DGX Stock Holding History

HighTower Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,000
Closed -$3K – 3333
2021
Q3 		$3K Buy
+10,000
New +$1.46M ﹤0.01% 3079

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

HighTower Advisors's DGX Position: Q1 2026 in Review

HighTower Advisors increased its Quest Diagnostics (DGX) stake by 45% in Q1 2026, buying an estimated $3.63M and bringing the position to 60,014 shares worth $11.8M. The position accounts for 0.01% of the portfolio, ranked #811.

HighTower Advisors first reported a position in DGX in Q2 2013 and has held it in 52 quarters since. The position peaked at $13.9M in Q4 2021. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • HighTower Advisors held 60,014 shares of Quest Diagnostics worth $11.8M as of Q1 2026.
  • HighTower Advisors bought 18,667 Quest Diagnostics shares in Q1 2026, an estimated $3.63M.
  • Quest Diagnostics made up 0.01% of HighTower Advisors's portfolio in Q1 2026, its #811 holding.
  • HighTower Advisors first reported a position in Quest Diagnostics in Q2 2013 and has held it in 52 quarters since.
  • HighTower Advisors's Quest Diagnostics position peaked at $13.9M in Q4 2021.
  • 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.